# Owen Smith

> Owen Smith is a Series A investor at 4BIO Capital (London) backing Medical and Life Science. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [4BIO Capital](https://shizune.co/investors/profile/4bio-capital-partners)
- Location: London, United Kingdom
- Total investments: 7
- Last investment: May 2026
- Lead investor: 71%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/owen-smith-50b55b39/

Owen Smith is a Series A investor at 4BIO Capital in London focused on Medical and Life Science. Owen Smith - Principal @ 4BIO Capital

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 3 | 43% |
| Life Science | 3 | 43% |
| Biotechnology | 3 | 43% |
| Therapeutics | 2 | 29% |
| Biopharma | 1 | 14% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 71% |
| Series B | 1 | 14% |
| Funding Round | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 29% |
| United Kingdom | 2 | 29% |
| France | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cytospire Therapeutics | Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers. | $82.6M | Series A | May 05, 2026 |  |
| March Biosciences | March Biosciences is a clinical-stage cell therapy company that focuses on developing CAR-T cell strategies to address hematological cancers. | $28.4M | Series A | Oct 23, 2024 |  |
| ViaNautis | Precision Solutions | $24.6M | Series A | Nov 13, 2023 |  |
| Entact Bio | Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed tocreate enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins. | $81M | Series A | Dec 06, 2022 |  |
| SparingVision | SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat allgenetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide. | $74.9M | Series B | Sep 14, 2022 |  |
| SparingVision | SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat allgenetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide. | $48.8M |  | Oct 21, 2020 |  |
| SparingVision | SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat allgenetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide. | $53.9M | Series A | Oct 21, 2020 |  |

7 of 7 investments shown.

## Co-investors
- [Jeito Capital](https://shizune.co/investors/profile/jeito-capital) — VC Fund, 4 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 3 deals together
- [UPMC Enterprises](https://shizune.co/investors/profile/upmc-enterprises) — VC Fund, 3 deals together
- [Ysios Capital](https://shizune.co/investors/profile/ysios-capital) — VC Fund, 3 deals together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 2 deals together
- [Foundation Fighting Blindness](https://shizune.co/investors/profile/foundation-fighting-blindness) — VC Fund, 2 deals together

## About 4BIO Capital

VC Fund · London, United Kingdom

4BIO Ventures is a London-based firm investing in venture capital and public equities in life sciences. They are focused on advanced therapies addressing high unmet medical and social needs.4BIO Capital Partners is an emerging asset manager focusing on private equity and venture capital in high growth and high return segments of biotech -biologics, gene and cell therapy and bioinformatics.

5 contacts available at 4BIO Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Andrew Kozlov | Managing Partner | https://shizune.co/investors/profile/andrey-kozlov |
| Dmitry Kuzmin | Managing Partner | https://shizune.co/investors/profile/dmitry-kuzmin |
| Kieran Mudryy | Partner | https://shizune.co/investors/profile/kieran-mudryy |
| Owen Smith | Principal | https://shizune.co/investors/profile/owen-smith-b474 |
| Vasily Fedorin | Principal | https://shizune.co/investors/profile/vasily-fedorin |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Owen Smith invest in?

Owen Smith invests primarily in Medical, Life Science and Biotechnology startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Owen Smith last invest?

The most recent investment recorded for Owen Smith closed in May 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co